Daniel Obi-Ofodile, MD
Family Medicine · Pearland, TXNPI 1639489628
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $408 of the $508 with a category attached, or 80.3%. 7 manufacturers reported payments, led by Melinta Therapeutics, LLC at 24.1% of the total. Reporting peaked in 2019 at $268 and has fallen 62.7% since, to $100 in 2023. That places this record below the midpoint for family medicine clinicians in TX, where the typical reported total is $436.
Across 13 payments — averaging $39.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Melinta Therapeutics, LLC$122
- E.r. Squibb & Sons, L.L.C.$121
- Johnson & Johnson$113
- Genentech USA, Inc.$59
- AbbVie$50
- AstraZeneca$23
- plus $19 from 1 others
Across 15 payments — averaging $4170.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Partner Therapeutics, Inc.$30K
- AstraZeneca$20K
- Chiesi USA, Inc.$13K
What the payments were for
- Food & beverage$40880%
- Education$10020%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Melinta Therapeutics, LLC | 1 | $122 |
| E.r. Squibb & Sons, L.L.C. | 2 | $121 |
| Johnson & Johnson | 4 | $113 |
| Genentech USA, Inc. | 3 | $59 |
| AbbVie | 1 | $50 |
| AstraZeneca | 1 | $23 |
| Boston Scientific | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Baxdela$122
How this compares
$508 in reported general payments places this provider in the 50th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 11 | $10,314 |
| Oxybutynin Chloride ErOxybutynin Chloride | 16 | $563 |
| Benztropine Mesylate | 11 | $413 |
| Pantoprazole Sodium | 11 | $121 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Pearland
- Joanna GutierrezPearland$82K
- Carlos CamposNew Braunfels$1.5M
- Aaron KingSan Antonio$1.1M
- Bradley WassonArlington$734K
- Cynthia BrinsonAustin$402K
- Michael MendezLubbock$368K
- Sang Tae KimAmarillo$368K
- Sumit PerakathuHarlingen$342K
- Joel SolisMcAllen$324K
- Robert CampbellFort Worth$318K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.